Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018124538) NANO-LIPOSOMAL CARRIER COMPOSITION WITH COMPLEX INCLUSIVE OF CAS9 PROTEIN, KRAS GENE EXPRESSION-INHIBITING GUIDE RNA AND CATIONIC POLYMER LOADED THEREIN AND THERAPEUTIC AGENT COMPRISING SAME FOR COLORECTAL CANCER RESISTANT TO ANTICANCER AGENT DUE TO KRAS GENE MUTATION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/124538 International Application No.: PCT/KR2017/014453
Publication Date: 05.07.2018 International Filing Date: 11.12.2017
IPC:
A61K 9/127 (2006.01) ,C12N 9/22 (2006.01) ,C12N 15/113 (2010.01) ,A61K 39/395 (2006.01) ,A61K 47/68 (2017.01) ,A61K 47/69 (2017.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
10
Dispersions; Emulsions
127
Liposomes
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9
Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14
Hydrolases (3.)
16
acting on ester bonds (3.1)
22
Ribonucleases
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
[IPC code unknown for A61K 47/68][IPC code unknown for A61K 47/69]
Applicants:
주식회사 무진메디 MOOGENE MEDI CO., LTD. [KR/KR]; 경기도 수원시 영통구 광교로 147, 경기바이오센터 402호(이의동) (Iui-dong) Gyeonggi Bio Center #402, 147, Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16229, KR
Inventors:
류지연 RYU, Jee-Yeon; KR
유경남 YU, Kyeong-Nam; KR
Agent:
이한욱 LEE, Han-Ook; KR
Priority Data:
10-2016-018215329.12.2016KR
Title (EN) NANO-LIPOSOMAL CARRIER COMPOSITION WITH COMPLEX INCLUSIVE OF CAS9 PROTEIN, KRAS GENE EXPRESSION-INHIBITING GUIDE RNA AND CATIONIC POLYMER LOADED THEREIN AND THERAPEUTIC AGENT COMPRISING SAME FOR COLORECTAL CANCER RESISTANT TO ANTICANCER AGENT DUE TO KRAS GENE MUTATION
(FR) COMPOSITION DE SUPPORT NANOLIPOSOMALE AVEC COMPLEXE INCLUANT LA PROTÉINE CAS9, L'ARN GUIDE INHIBANT L'EXPRESSION DU GÈNE KRAS ET UN POLYMÈRE CATIONIQUE CHARGÉ DANS CELLE-CI ET AGENT THÉRAPEUTIQUE LA COMPRENANT POUR UN CANCER COLORECTAL RÉSISTANT À UN AGENT ANTICANCÉREUX EN RAISON D'UNE MUTATION DU GÈNE KRAS
(KO) Cas9 단백질, KRAS 유전자의 발현을 억제하는 가이드 RNA 및 양이온성 폴리머의 복합체가 봉입된 나노 리포좀 전달체 조성물 또는 이를 함유하는 KRAS 유전자 변이에 따른 항암제 저항성 대장암 치료제
Abstract:
(EN) The present invention relates to a nano-liposomal carrier composition in which a complex including a Cas9 protein, a guide RNA inhibitory of KRAS gene expression, and a cationic polymer is loaded, or a therapeutic agent comprising the same for colorectal cancer resistant to anticancer agents due to KRAS gene mutation therein. Cetuximab, which is used as a therapeutic agent for metastatic colorectal cancer at present, is effective only for patients with KRAS wild-type colorectal cancer. Cetuximab has the fatal drawback in that given a continual treatment with cetuximab, even patients with KRAS wild-type colorectal cancer may develop KRAS mutant colorectal cancer in 60-80% cases. However, the use of the nano-liposomal composition of the present invention can not only fundamentally suppress the mutation of KRAS, which is an oncogene in colorectal cancer, but also very effectively treat KRAS mutant metastatic colorectal cancer.
(FR) La présente invention concerne une composition de support nanoliposomale dans laquelle un complexe comprenant une protéine Cas9, un ARN guide inhibant l'expression du gène KRAS et un polymère cationique est chargé, ou un agent thérapeutique le comprenant pour un cancer colorectal résistant aux agents anticancéreux en raison d'une mutation du gène KRAS dans celui-ci. Le cétuximab, qui est utilisé en tant qu'agent thérapeutique pour le cancer colorectal métastatique, est efficace uniquement pour les patients atteints d'un cancer colorectal de type sauvage KRAS. Le cétuximab présente l'inconvénient fatal en ce que, étant donné un traitement continu avec le cétuximab, même des patients atteints d'un cancer colorectal de type sauvage KRAS peuvent développer un cancer colorectal à mutation de KRAS dans 60 à 80 % des cas. Cependant, l'utilisation de la composition nanoliposomale de la présente invention peut non seulement supprimer fondamentalement la mutation de KRAS, qui est un oncogène dans le cancer colorectal, mais également traiter de manière très efficace le cancer colorectal métastatique à mutation de KRAS.
(KO) 본 발명은 Cas9 단백질, KRAS 유전자의 발현을 억제하는 가이드 RNA 및 양이온성 폴리머의 복합체가 봉입된 나노 리포좀 전달체 조성물 또는 이를 함유하는 KRAS 유전자 변이에 따른 항암제 저항성 대장암 치료제에 관한 것이다. 현재 전이성 대장암 치료제로 사용되고 있는 Cetuximab의 경우 KRAS 정상형 대장암 환자에게만 효과가 있고 KRAS 정상형 대장암 환자이더라도 지속적으로 Cetuximab의 치료를 받으면, 60~80%의 환자가 KRAS 돌연변이형으로 발전할 수 있는 치명적인 단점을 가지고 있다. 그렇지만, 본 발명의 나노 리포좀 조성물을 이용할 경우, 대장암 유발 유전자인 KRAS의 돌연변이를 근본적으로 억제할 수 있을 뿐만 아니라, KRAS 돌연변이형 전이성 대장암의 치료를 매우 효과적으로 수행할 수 있다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)